Minimal Residual Disease in Melanoma

1. Front Matter

   Pages I-XII

   PDF

2. Biology of Micrometastases and Advances in Methods for Detection

   1. Front Matter

      Pages 1-1

      PDF

   2. The Biology of Melanoma Micrometastases

      • R. L. Barnhil

      Pages 3-13

   3. Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping

      • K. Pantel, M. Otte

      Pages 14-24

   4. Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells

      • N. Max, K. Wolf, B. Spike, E. Thiel, U. Keilholz

      Pages 25-31

   5. Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems

      • R. Jung, K. Soondrum, W. Krüger, M. Neumaier

      Pages 32-39

   6. Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients

      • Ø. Fodstad, R. Faye, H. K. Høifødt, E. Skovlund, S. Aamdal

      Pages 40-50

   7. Rapid Enrichment and Detection of Melanoma Cells from Peripheral Blood Mononuclear Cells by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining

      • C. Siewert, M. Herber, N. Hunzelmann, Ø. Fodstad, S. Miltenyi, M. Assenmacher et al.

      Pages 51-60

3. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow

   1. Front Matter

      Pages 61-61

      PDF

   2. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned?

      • R. A. Ghossein, S. Bhattacharya, D. G. Coit

      Pages 63-77

   3. The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma

      • B. Taback, D. L. Morton, S. J. O’Day, D.-H. Nguyen, T. Nakayama, D. S. B. Hoon

      Pages 78-92

   4. Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients

      • B. Schittek, H.-J. Blaheta, U. Ellwanger, C. Garbe

      Pages 93-104

   5. Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR

      • S. Seiter, G. Rappl, W. Tilgen, S. Ugurel, U. Reinhold

      Pages 105-112

   6. Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients

      • A. Benez, U. Schiebel, G. Fierlbeck

      Pages 113-117

   7. Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time

      • V. Waldmann, J. Wacker, M. Deichmann, A. Jäckel, M. Bock, H. Näher

      Pages 118-125

4. Detection of Minimal Residual Disease in Sentinel Nodes

   1. Front Matter

      Pages 127-127

      PDF

   2. The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas

      • D. Bachter, C. Michl, H. Büchels, H. Vogt, B. R. Balda

      Pages 129-136

   3. Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma

      • H.-J. Blaheta, B. Schittek, H. Breuninger, C. Garbe

      Pages 137-146

5. Early Recognition and Monitoring by Serological Markers

   1. Front Matter

      Pages 147-147

      PDF

   2. Monitoring Malignant Melanoma with the S-100B Tumour Marker

      • J. M. G. Bonfrer, C. M. Korse

      Pages 149-157

Knowledge about diagnostic procedures in melanoma has in­ creased rapidly within the past few years. Single tumor cells have been identified in normal tissue such as sentinel lymph nodes, as well as in bone marrow, peripheral blood, and other bodily fluids and cells, by molecular technologies. The introduction of polymerase chain reaction-based methods can be regarded as a prototype of this dramatic development towards molecular approaches in new diagnostic procedures. This fact opens up the possibility of clinical use in patients and of influencing treatment strategies. Considerable discrepancies have been described, how­ ever, in the success rates of these new techniques for the detec­ tion of minimal residual disease in cancer patients. Despite fav­ orable results reported by different groups of investigators, it will take several years to define the clinical and pathophysiological relevance of new diagnostic procedures. The 1st International Symposium "Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance of Microme­ tastases", held in September 1999 in Homburg/Saar, Germany, fo­ cused on recent developments in this particular area of cancer re­ search. The purpose of the meeting was to stimulate discussion and exchange of new data and ideas by renowned international scientists. The aim of this volume is to summarize major topics of basic research and clinical investigations presented by invited experts in this fascinating but still. controversial field of melanoma re­ search.

• Staging
• Tumormarker
• diagnostics
• metastatic disease
• sentinel node
• therapy
• tissue
• tumor marker

• Universitätskliniken des Saarlandes Haut- und Poliklinik, Homburg/Saar, Germany

  Uwe Reinhold, Wolfgang Tilgen

Policies and ethics